Primary gastrointestinal lymphoma (PGL) is known to account for 40% of all extranodal non-Hodgkin's lymphomas (NHLs) and between 4% to 12% of all NHLs. The small intestine is the site of presentation in 20-30% of cases, with the terminal ileum usually involved. Duodenal localizations have always been thought to be rare, but are presently growing in incidence. We herein report on a case of Stage IV primary duodenal FCL, located to the second portion of the duodenum with concomitant minimal bone marrow involvement. The patient was frontline approached with a conservative combined modality treatment consisting of 4 weekly infusions of the chimeric human-murine IgG1 mono-clonal antibody against the B-cell surface antigen CD-20, Rituximab (375 mg/m2) and consolidation 3D conformal external beam radiotherapy up to a total dose of 36 Gy given into 20 fractions to the involved duodenal portion. Six years after treatment has been completed, the patient is free from disease with no treatment-related toxicity.
Primary duodenal follicular lymphoma : 6-years complete remission after combined radio-immunotherapy / P. Franco, A.R. Filippi, P. Ciammella, A. Botticella, A. Namysl Kaletka, A. De Crescenzo, C. Tarella, U. Ricardi. - In: ACTA GASTRO-ENTEROLOGICA BELGICA. - ISSN 1784-3227. - 74:2(2011), pp. 337-342.
|Titolo:||Primary duodenal follicular lymphoma : 6-years complete remission after combined radio-immunotherapy|
|Parole Chiave:||Radiotherapy; Primary duodenal lymphoma; Follicula lymphoma; Rituximab|
|Settore Scientifico Disciplinare:||Settore MED/15 - Malattie del Sangue|
|Data di pubblicazione:||2011|
|Appare nelle tipologie:||01 - Articolo su periodico|
File in questo prodotto:
|Primary duodenal follicula lymphoma Acta gastroenterol Belgica 2011.pdf||Publisher's version/PDF||Administrator Richiedi una copia|